Breaking News

BioPure Completes Construction of New Facility

Production is scheduled to begin in March 2022.

Biopharmaceutical fluid path component provider, BioPure, part of Watson-Marlow Fluid Technology Group (WMFTG), has received the keys for its custom-built facility at Dunsbury Park, with production due to begin in March 2022.
 
Beginning construction in 2019, the new facility is five times the size of the company’s previous two buildings combined and will provide additional capacity to support the company’s ongoing growth and provide service to its customers.
 
Comprising 120,000 sq. ft, this new facility will help to support BioPure’s ambitious vision, growth and commitment to supporting customers worldwide. The company’s key aims include simplifying production operations, lowering cGMP manufacturing costs and reducing process validation.
 
The new facility, based just 4 miles from the current site in Portsmouth, is now home to BioPure’s current team of 232 employees and aims to bring on a diverse range of new talent in manufacturing, engineering, production, design, assembly, logistics and administration. The expansion will create 130 new jobs across a range of disciplines and the company is looking for talented individuals to join the team.
 
To ensure customers receive products and services of the highest quality, the company will continue to use existing production equipment at the new site. There will be no change in raw materials, nor will there be any change in processing equipment or process methods. Revalidation of each molding machine and metrology comparison with products from the old manufacturing process has ensured that there is no change to the fit, form or function of BioPure’s products.
 
Steve Feasey, manager director of BioPure, commented, “This is a very exciting time for BioPure, with demand for our products increasing year on year. We’re thrilled to get the keys to our new facility, providing increased capacity for us to deliver our high-quality fluid path components and strengthen our support for the pharmaceutical and biotechnology industry. This demonstrates our ongoing commitment to improving our customer service and our team is excited to start work from this state-of-the-art facility. We look forward to continuing to grow and develop more market-leading fluid management solutions.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters